Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Bendamustine Approved in Singapore: SymBio
February 15, 2010
- Kowa to Launch Livalo Soon in the US
February 15, 2010
- Banyu, Schering-Plough Copromote Mutual Products to Offer New Options for Asthma, Allergy
February 15, 2010
- Astellas to Enter PII for Antibody Drug for Ovarian Cancer
February 15, 2010
- Novartis Aims to Become Top-3 Oncology Company in Japan
February 15, 2010
- Daiichi Sankyo Begins Global PIII Trial for Edoxaban for Prevention of VTE
February 15, 2010
- NBI Aims at RLS to Account for 15% of BI-Sifrol Sales
February 15, 2010
- Application for Eritoran Postponed: Eisai
February 15, 2010
- Taiho to Promote Aloxi with 800 MRs
February 15, 2010
- FUJIFILM to Embark on Generic Business
February 15, 2010
- IHI, UMN Pharma to Create Joint Venture for Flu Vaccines
February 15, 2010
- Fuji Pharma, Mochida to Jointly Develop G-CSF Biosimilar
February 15, 2010
- QOL, Growell, Medipal to Operate Pharmacies for Elderly Consumers
February 15, 2010
- BioNumerik Initiates Global PIII for Tavocept
February 15, 2010
- Toho, Itochu to Create Joint Venture in China with Local Drug Wholesaler
February 15, 2010
- AnGes Completes Enrollment in PIII Trial for Allovectin-7
February 15, 2010
- DSP to Transfer Growth Hormone Business to JCR
February 8, 2010
- PMDA Needs Internal Renovation: Prof. Kami
February 8, 2010
- Pregabalin to Drive Pfizer's Primary Case Business: Mr Harada
February 8, 2010
- Panel on Unapproved Drugs to Hold 1st Meeting
February 8, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…